Singapore Articles

Pages

CT acquires pacritinib from S*BIO

Cell Therapeutics (CT) has gained worldwide rights to S*BIO's pacritinib, a highly selective oral JAK2 (Janus associated kinase 2) inhibitor that demonstrated "encouraging" clinical activity in...

Read article ›
CT to acquire pacritinib from S*BIO

Cell Therapeutics (CT) has agreed to acquire worldwide rights to S*BIO's pacritinib, a highly selective JAK2 inhibitor. Pacritinib is an oral JAK2 (Janus associated kinase 2) selective inhibitor...

Read article ›

Pages